Cytogen raises $10 million
The recent surge in publicity-and stock price-surrounding Cytogen has been accompanied by a private stock placement that has stuffed the Princeton, NJ-based company's coffers with $10 million. Investors picked up an aggregate of 1,172,332 shares of
The recent surge in publicity-and stock price-surrounding Cytogen has been accompanied by a private stock placement that has stuffed the Princeton, NJ-based company's coffers with $10 million. Investors picked up an aggregate of 1,172,332 shares of common stock at $8.53 per share. They will also receive warrants to purchase an aggregate of the same number of shares of common stock at an exercise price of $12.80 per share. Cytogen executives plan to use the proceeds to reacquire North American and Latin American marketing rights for the company's radiopharmaceutical, Quadramet.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
